NATCO Pharma credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
706706273363165
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−1,423−1,423−2,224−1,033−686
0.08×0.08×0.04×0.06×0.03×
−0.15×−0.15×−0.29×−0.18×−0.14×
0.49×0.49×0.12×0.21×0.18×
−1.35×−0.99×−1.01×−0.59×−0.73×
33.51×33.51×82.04×81.49×53.23×
7.1%7.1%3.5%5.8%3.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCOPHARM₹787.55

NATCO Pharma Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYZYDUSLIFESUNPHARMALALPATHLABNEULANDLABNHSAILIFECOHANCEMcap ₹14,097 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt165.0363.2273.1706.4706.4
Net Debt-686.3-1,033.2-2,223.7-1,422.7-1,422.7
Total Debt/Equity0.030.060.040.080.08
Net Debt/Equity-0.14-0.18-0.29-0.15-0.15
Total Debt/EBITDA0.180.210.120.490.49
Net Debt/EBITDA-0.73-0.59-1.01-0.99-1.35
Interest Coverage (EBIT/Interest)53.2381.4982.0433.5133.51
Total Debt/Total Capital %3.275.843.467.127.12
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.